Serious tadalafil adverse events are uncommon, but several symptoms require rapid recognition because delayed assessment can have important consequences. Current U.S. labeling advises emergency medical attention for an erection lasting more than 4 hours, medical attention for sudden loss of vision, and prompt medical attention for sudden decrease or loss of hearing.
These serious events should not be interpreted in the same way as common reactions such as headache, dyspepsia or back pain. Some serious events appear primarily in postmarketing reports, which means their frequency cannot usually be calculated reliably and a temporal association with tadalafil does not by itself prove that tadalafil caused the event.
This page focuses on recognizing serious events and understanding the action language used in current labeling. Routine tolerability belongs on the common tadalafil side-effects page, the broad safety taxonomy on the tadalafil side-effects hub, and risk-factor management and general precautions on the tadalafil warnings page.
The most important distinction on a serious-side-effects page is the required level of response. Current labeling uses different wording for different events, and those distinctions should be preserved rather than reducing every serious reaction to a generic 'call your doctor.'
An erection lasting more than 4 hours carries emergency-treatment language. Sudden vision loss and sudden hearing decrease or loss also require stopping tadalafil and obtaining medical attention, although the precise wording differs.
The table below summarizes the current label-based action framework.
| Symptom or event | Why it matters | Label-based response |
|---|---|---|
| Erection lasting more than 4 hours | Prolonged erection can progress to priapism and cause irreversible erectile-tissue damage | Seek emergency medical attention |
| Sudden loss of vision in one or both eyes | May be a sign of NAION, which can cause permanent vision loss | Stop tadalafil and seek medical attention |
| Sudden decrease or loss of hearing | Serious otologic event reported with PDE5 inhibitors | Stop tadalafil and seek prompt medical attention |
| Serious hypersensitivity reaction | Potentially severe immune or skin reaction; serious hypersensitivity is a contraindication | Seek urgent medical care |
| Chest pain, dizziness or nausea during sexual activity | May signal clinically important cardiovascular stress | Stop sexual activity and seek immediate medical attention |
Frequency and seriousness describe different properties. Headache can be relatively common while generally belonging to a tolerability category, whereas an uncommon prolonged erection or sudden sensory loss can demand urgent action because of the possible consequence.
Serious events also come from different evidence sources. Some warnings are supported by class experience, observational evidence or spontaneous postmarketing reports rather than by a clinical-trial table with a simple percentage.
For that reason, this page does not assign unsupported frequency estimates such as 'one in X users' to serious tadalafil reactions.
| Safety category | Example | Main question |
|---|---|---|
| Common adverse reaction | Headache or dyspepsia | How often was it reported and how tolerable was it? |
| Serious warning event | Prolonged erection or sudden sensory loss | Can delayed recognition cause serious harm? |
| Postmarketing signal | NAION or sudden hearing loss | What was reported, and what can or cannot be concluded about causality? |
| Contraindication | Known serious hypersensitivity | Should tadalafil be used in this circumstance? |
Current CIALIS labeling reports rare prolonged erections lasting more than 4 hours and priapism within the PDE5-inhibitor class. It defines priapism in this context as a painful erection lasting more than 6 hours, but patients are not told to wait 6 hours before seeking care.
The action threshold is an erection lasting more than 4 hours, whether painful or not. The label warns that untreated priapism can cause irreversible damage to erectile tissue.
This distinction is clinically important: the emergency threshold begins before the label's descriptive definition of painful priapism is reached.
| Time / condition | Interpretation |
|---|---|
| Normal erectile response that subsides | Not the prolonged-erection warning described here |
| Erection lasting more than 4 hours | Seek emergency medical attention whether painful or not |
| Painful erection lasting more than 6 hours | Label description of priapism within this warning context |
| Delayed treatment of priapism | Can result in irreversible erectile-tissue damage |
Tadalafil's well-known extended response window and the prolonged-erection warning describe completely different phenomena. The response window means erectile responsiveness may remain supported when sexual stimulation occurs; it does not mean an erection should persist continuously.
An erection lasting more than 4 hours is therefore not an expected expression of tadalafil's long duration. It is an emergency warning sign regardless of the drug's longer clinical response window.
The clinical meaning of the extended response period is covered separately on the tadalafil 36-hour page.
| Concept | Meaning |
|---|---|
| Up-to-36-hour response window | Potential period of supported erectile responsiveness with sexual stimulation |
| Continuous erection | Not what the 36-hour claim means |
| Erection >4 hours | Emergency warning sign |
Current CIALIS labeling advises caution in patients with conditions that may predispose them to priapism, including sickle cell anemia, multiple myeloma and leukemia. It also identifies anatomical penile conditions such as angulation, cavernosal fibrosis and Peyronie's disease as relevant risk contexts.
These factors help explain why the warning is not merely theoretical, but they do not allow prediction of exactly who will develop a prolonged erection. Recognition of the >4-hour threshold remains important regardless of whether a known predisposing condition is present.
The broader question of who requires additional caution with tadalafil belongs on the warnings and precautions page.
| Predisposing context listed in labeling | Examples |
|---|---|
| Hematologic condition | Sickle cell anemia, multiple myeloma, leukemia |
| Anatomical penile condition | Angulation, cavernosal fibrosis, Peyronie's disease |
| Does absence of these factors eliminate risk? | No |
Current labeling instructs patients to stop tadalafil and seek medical attention if sudden loss of vision occurs in one or both eyes. Such an event may represent non-arteritic anterior ischemic optic neuropathy, or NAION, a rare condition that can cause decreased vision including permanent loss.
NAION has been reported rarely after marketing in temporal association with PDE5 inhibitors, including tadalafil. The label carefully distinguishes this temporal association from proof that tadalafil directly caused each event.
Sudden vision loss should therefore be treated seriously even though the causal relationship is not established for every reported case.
| Vision issue | Interpretation |
|---|---|
| Sudden loss of vision in one or both eyes | Stop tadalafil and seek medical attention |
| Possible explanation | NAION |
| Potential consequence of NAION | Permanent vision loss |
| Postmarketing temporal association | Reported |
| Direct tadalafil causation proven in every case | No |
The current CIALIS label notes that NAION is uncommon in the general population and summarizes observational case-crossover studies of PDE5 inhibitors as a class that found approximately a two-fold statistical association between recent PDE5-inhibitor exposure and NAION.
Those observational findings do not prove a causal relationship. The label explicitly states that neither rare postmarketing reports nor the observational association substantiate that PDE5 inhibitors directly cause NAION.
Several patients in postmarketing reports also had established anatomical or vascular NAION risk factors. Detailed management of prior NAION and other susceptibility factors belongs primarily on the warnings page.
| NAION evidence point | What it supports |
|---|---|
| Rare postmarketing reports | Temporal association exists |
| Observational studies | Reported approximately two-fold statistical association for PDE5 inhibitors as a class |
| Observational association | Does not establish direct causation |
| Known background risk factors | May contribute independently to NAION risk |
Tadalafil labeling also lists less common ophthalmologic events such as blurred vision, changes in color vision, eye pain and other ocular complaints. Those events should not be automatically labeled as NAION.
The serious-action wording is specifically important for sudden loss of vision in one or both eyes. A user should not attempt to distinguish a potentially serious sudden visual event from a harmless one solely by comparing symptoms with an online list.
The practical distinction is therefore between routine adverse-event reporting and an abrupt vision-loss warning that requires medical evaluation.
| Visual event | Same as confirmed NAION? |
|---|---|
| Blurred vision | No |
| Change in color vision | No |
| Sudden loss of vision | May represent NAION and requires medical attention |
Current CIALIS labeling instructs patients to stop tadalafil and seek prompt medical attention if sudden decrease or loss of hearing occurs. Reported cases may also be accompanied by tinnitus or dizziness.
These events have been reported after marketing in temporal association with PDE5 inhibitors, including tadalafil. Available follow-up information has often been limited, and other medical conditions or risk factors may have contributed.
The label therefore does not claim that tadalafil directly caused every sudden-hearing event, but the uncertainty about causation does not weaken the recommendation for prompt assessment.
| Hearing symptom | Label context |
|---|---|
| Sudden decrease in hearing | Stop tadalafil and seek prompt medical attention |
| Sudden hearing loss | Stop tadalafil and seek prompt medical attention |
| Tinnitus accompanying sudden hearing change | Reported in some cases |
| Dizziness accompanying sudden hearing change | Reported in some cases |
| Direct causal relationship established in every case | No |
Sudden hearing loss appears mainly in postmarketing safety reporting rather than as a common event with a defined denominator in placebo-controlled trials. Spontaneous reports come from an uncertain-size population, so a reliable incidence percentage cannot normally be calculated.
This is a recurring principle in serious-drug-safety interpretation: an event can be important enough to generate explicit warning language even when its exact frequency is unknown.
Giving a fabricated numerical risk would be less accurate than preserving the label's actual message: the event has been reported, causality is uncertain and prompt medical attention is advised.
| Question | Answer |
|---|---|
| Has sudden hearing loss been reported? | Yes |
| Can current spontaneous reports provide a reliable incidence percentage? | Generally no |
| Does unknown frequency mean the warning can be ignored? | No |
Current tadalafil labeling includes postmarketing hypersensitivity reactions such as urticaria and serious skin reactions including Stevens-Johnson syndrome and exfoliative dermatitis. These events are fundamentally different from routine common side effects.
Known serious hypersensitivity to tadalafil is also a formal contraindication. This means the issue spans two regulatory categories: a severe hypersensitivity event may appear in adverse-event reporting, while a history of serious tadalafil hypersensitivity describes a circumstance in which subsequent use is contraindicated.
The formal contraindication framework is covered in greater detail on the tadalafil contraindications page.
| Hypersensitivity issue | Label status |
|---|---|
| Urticaria | Reported postmarketing |
| Stevens-Johnson syndrome | Serious hypersensitivity/skin reaction reported |
| Exfoliative dermatitis | Serious reaction reported |
| Known serious hypersensitivity to tadalafil | Contraindication |
Serious cardiovascular and cerebrovascular events including myocardial infarction, sudden cardiac death, stroke and chest pain have been reported after marketing in temporal association with tadalafil. Most, but not all, patients described in these reports had preexisting cardiovascular risk factors.
The current CIALIS label states that it is not possible to determine whether such events were directly related to tadalafil, sexual activity, underlying cardiovascular disease, a combination of those factors or another cause. Presenting myocardial infarction or stroke as a simple proven tadalafil side effect would therefore overstate the evidence.
Current patient counseling also advises stopping sexual activity and seeking immediate medical attention for symptoms such as chest pain, dizziness or nausea during sex. The broader cardiovascular-risk framework belongs on the tadalafil warnings page.
| Cardiovascular point | Current label interpretation |
|---|---|
| Myocardial infarction, stroke and other serious cardiovascular events have been reported | Yes |
| Many reported patients had cardiovascular risk factors | Yes |
| Tadalafil is proven to have directly caused every reported event | No |
| Chest pain, dizziness or nausea during sexual activity | Stop sexual activity and seek immediate medical attention |
Current CIALIS postmarketing labeling also lists events such as seizure and seizure recurrence, transient global amnesia, retinal vein or artery occlusion and visual-field defects. Their presence in the postmarketing section means they were identified after approval and selected for inclusion because of factors such as seriousness, reporting frequency or lack of a clear alternative explanation.
It does not mean that each event has a known tadalafil-specific incidence or a proven direct causal mechanism. The same postmarketing limitation applies: voluntary reporting from an uncertain-size population makes reliable frequency estimation difficult.
This page prioritizes the events with explicit patient-recognition or action language rather than turning the postmarketing section into an undifferentiated list of diagnoses.
| Other reported category | Examples in current postmarketing labeling | What can be concluded |
|---|---|---|
| Neurologic | Seizure, seizure recurrence, transient global amnesia | Reported postmarketing; frequency and causality not reliably established |
| Ophthalmologic | Visual-field defect, retinal vein occlusion, retinal artery occlusion | Reported postmarketing; not interchangeable with the specific NAION warning |
The current CIALIS label explicitly states that postmarketing adverse reactions are reported voluntarily from a population of uncertain size. As a result, it is not always possible to estimate frequency reliably or establish a causal relationship to tadalafil exposure.
Temporal association simply means that an event occurred after or around the time tadalafil was used. Other explanations may include underlying disease, sexual activity, concomitant medications, anatomical risk factors or unrelated events.
This distinction is especially important for serious outcomes because overstating causality can be as misleading as minimizing a warning that requires urgent recognition.
| Evidence statement | Meaning |
|---|---|
| Reported after tadalafil exposure | Temporal association |
| Reported voluntarily postmarketing | No reliable denominator for incidence |
| Listed in prescribing information | Important enough to communicate; not automatically proof of causation |
| Explicit warning action | Should be followed even when exact causality or frequency is uncertain |
These terms overlap but are not interchangeable. A serious adverse event describes an important clinical event; a warning explains a clinically significant risk and how it should be managed; a contraindication identifies a circumstance in which tadalafil should not be used.
For example, sudden hearing loss appears in postmarketing experience and carries warning language, while known serious tadalafil hypersensitivity is a contraindication. Organic nitrates and guanylate cyclase stimulators such as riociguat are also contraindications rather than side effects.
The broader classification is summarized on the master side-effects page, while formal exclusions belong on the contraindications page.
| Category | Example | Meaning |
|---|---|---|
| Serious event / warning sign | Sudden hearing loss | Recognize and act promptly |
| Warning | Risk of prolonged erection | Provides action and precaution context |
| Contraindication | Known serious tadalafil hypersensitivity | Drug should not be used in that circumstance |
| Contraindicated interaction | Organic nitrates or riociguat | Separate drug-combination risk |
A serious symptom during tadalafil use may also arise in an interaction context. Organic nitrates are contraindicated with tadalafil because the combination can markedly potentiate blood-pressure lowering, while other vasodilating medicines can contribute to symptomatic hypotension.
This is why a serious symptom cannot always be interpreted by reading an adverse-effects list alone. Medication context can materially change the safety assessment.
The interaction framework belongs on the tadalafil drug-interactions page, with the contraindicated nitrate combination covered on the tadalafil and nitrates page.
| Safety issue | Primary category |
|---|---|
| Priapism | Serious adverse-event / warning context |
| Sudden hearing loss | Serious postmarketing / warning context |
| Tadalafil + organic nitrate | Contraindicated interaction |
| Hypotension from additive vasodilators | Interaction / warning context |
Serious-event warnings should not be converted into a simple dose-threshold rule. Current labeling does not state that a particular tadalafil strength eliminates risks such as priapism, sudden vision loss or sudden hearing loss.
Likewise, postmarketing reports generally do not provide the controlled denominator needed to calculate a reliable serious-event rate for each strength. Common adverse-reaction dose patterns from clinical trials should not be extrapolated to these uncommon serious events.
Strength and regimen selection belong on the tadalafil dosage page; the presence of a serious warning sign should be interpreted according to the warning itself.
| Claim | Supported? |
|---|---|
| A low tadalafil dose eliminates serious-event risk | No |
| A precise priapism or NAION percentage can be assigned to every strength from current labeling | No |
| Common side-effect dose trends can predict rare serious-event risk | No |
Cialis and FDA-approved generic tadalafil contain the same active ingredient, so the major tadalafil warnings involving prolonged erection, sudden vision loss and sudden hearing loss apply to the active drug rather than being unique to the Cialis brand.
Specific product labels can differ in formatting, indication context and inactive ingredients, but current U.S. generic tadalafil labeling carries the same core serious warnings and postmarketing safety concepts.
Brand-specific product information belongs on the Cialis page.
| Serious-safety issue | CIALIS | FDA-approved generic tadalafil |
|---|---|---|
| Prolonged erection / priapism warning | Yes | Yes |
| Sudden vision-loss warning | Yes | Yes |
| Sudden hearing-loss warning | Yes | Yes |
| Serious hypersensitivity contraindication | Yes | Yes |
When evaluating a possible serious tadalafil reaction, the important information is not just whether tadalafil was taken. The type of symptom, timing, duration, associated symptoms, other medicines and underlying medical context can all affect interpretation.
For certain symptoms, however, current labeling gives explicit action instructions that do not depend on first proving tadalafil caused the event. Sudden vision loss, sudden hearing loss and an erection lasting more than 4 hours are examples.
That distinction helps prevent a dangerous delay caused by trying to establish causality before seeking assessment.
| Check | Question |
|---|---|
| Symptom | Is this a routine tolerability effect or an explicit serious warning sign? |
| Duration | For an erection, has it persisted for more than 4 hours? |
| Sensory change | Was there sudden loss or major decrease in vision or hearing? |
| Associated symptoms | Is hearing change accompanied by tinnitus or dizziness, or are cardiovascular symptoms present? |
| Other medicines | Could a contraindicated or blood-pressure-lowering interaction be involved? |
| Action language | Does current labeling call for emergency, immediate or prompt medical attention? |
The most important serious tadalafil warning signs to recognize are an erection lasting more than 4 hours, sudden loss of vision and sudden decrease or loss of hearing. Current labeling assigns explicit medical-action language to each of these events.
Serious hypersensitivity, cardiovascular events and other neurologic or ophthalmologic events have also been reported, but their regulatory and evidentiary context differs. Postmarketing reports usually cannot provide a reliable incidence rate and do not automatically establish tadalafil as the direct cause.
This page therefore prioritizes recognition and action over unsupported probability estimates. General precautionary risk assessment belongs on the warnings page, formal exclusions on the contraindications page and medication-combination risks on the interaction pages.
Important serious warning signs include an erection lasting more than 4 hours, sudden loss of vision and sudden decrease or loss of hearing. Serious hypersensitivity reactions and other serious postmarketing events have also been reported.
Current labeling specifically instructs patients to seek emergency medical attention for an erection lasting more than 4 hours, whether painful or not. Other severe symptoms can require immediate or prompt medical assessment depending on the event.
Priapism has been reported with PDE5 inhibitors including tadalafil. Current CIALIS labeling describes rare prolonged erections lasting more than 4 hours and priapism as painful erections lasting more than 6 hours.
Current U.S. labeling advises emergency medical attention when an erection lasts more than 4 hours, whether it is painful or not. Patients should not wait until the erection has lasted 6 hours.
No. The up-to-36-hour claim refers to a period during which tadalafil may support erectile responsiveness when sexual stimulation occurs. A continuous erection lasting more than 4 hours is a medical emergency warning sign.
Untreated priapism can cause irreversible damage to erectile tissue. That is why current labeling advises emergency medical attention for any erection lasting more than 4 hours.
Rare cases of NAION, a condition that can cause permanent vision loss, have been reported in temporal association with PDE5 inhibitors including tadalafil. Current labeling instructs patients to stop tadalafil and seek medical attention for sudden vision loss.
No. NAION has been reported rarely after PDE5-inhibitor use and observational studies have found an association, but current labeling states that the available evidence does not substantiate a direct causal relationship.
Current CIALIS labeling instructs patients to stop tadalafil and seek medical attention for sudden loss of vision in one or both eyes because the event could represent NAION.
No. Blurred vision and other visual complaints are not automatically NAION. Sudden loss of vision is the key serious warning sign described in current labeling and requires medical assessment.
Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with tadalafil and other PDE5 inhibitors. Current labeling advises stopping tadalafil and seeking prompt medical attention if this occurs.
Yes. Current labeling notes that reported sudden hearing decrease or loss may be accompanied by tinnitus and dizziness.
A reliable incidence cannot be calculated from spontaneous postmarketing reports because they come from a population of uncertain size. The label therefore communicates the warning without assigning a precise frequency.
Stevens-Johnson syndrome has been reported among postmarketing hypersensitivity reactions associated with tadalafil. The report does not by itself establish a predictable incidence, but serious hypersensitivity to tadalafil is a formal contraindication.
Myocardial infarction, stroke and other serious cardiovascular events have been reported postmarketing in temporal association with tadalafil. Current labeling states that it is not possible to determine whether these events were caused by tadalafil, sexual activity, underlying cardiovascular disease, a combination of factors or another cause.
Current CIALIS patient counseling advises stopping sexual activity and seeking medical help right away for symptoms such as chest pain, dizziness or nausea during sex. The medication and interaction context should be communicated to healthcare professionals.
Seizure and seizure recurrence appear in current CIALIS postmarketing adverse-reaction reporting. Because these are spontaneous reports from an uncertain-size population, their incidence and direct causal relationship to tadalafil cannot be reliably established.
Current labeling does not provide a simple dose-by-dose incidence model for rare serious events such as priapism, NAION or sudden hearing loss. Common adverse-reaction dose trends should not be used to predict these uncommon events.
Cialis and FDA-approved generic tadalafil contain the same active ingredient and share the core serious tadalafil warning framework. Product-specific labeling should still be checked.
Many serious events were identified through postmarketing reports rather than controlled trials. Because those reports come from an uncertain-size population, frequency usually cannot be estimated reliably and causality may remain uncertain.